Abstract
Among the radiopharmaceuticals harnessed for palliation of bone pain in osseous metastases patients, 177Lu labeled phosphonates such as EDTMP (Ethylene diamine tetramethylene phosphonic acid) as well as DOTMP (1,4,7,10-tetraaza-cyclo-dodecane-1,4,7,10 tetraethylene phosphonic acid) and 188Re-labeled HEDP (1,1-hydroxyethylene diphosphonic acid) seem to be the most favorable for treatment of small and medium/large size bone lesions, respectively. A comparative assessment of 177Lu-EDTMP, 177Lu-DOTMP and 188Re-HEDP in osteosarcoma tumor cell line was carried out to evaluate their relative efficacy. It was found that 188Re-HEDP is more potent in induction of cell toxicity and apoptosis compared to the 177Lu-EDTMP and 177Lu-DOTMP, thus 188Re-HEDP might have great clinical significance.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
